Literature DB >> 23678379

Endoscopic ultrasonography in patients with elevated carbohydrate antigen 19-9 of obscure origin.

Jae Hoon Cheong1, Gwang Ha Kim, Ji Yoon Moon, Bong Eun Lee, Dong Yup Ryu, Dong Uk Kim, Hyung-Il Seo, Geun Am Song.   

Abstract

AIM: To evaluate the efficacy of endoscopic ultrasonography (EUS) in patients with elevated carbohydrate antigen (CA) 19-9 levels of obscure origin.
METHODS: Patients who had visited Pusan National University Hospital because of elevated serum CA 19-9 levels, between January 2007 and December 2009, were retrospectively enrolled. EUS had been performed on all subjects, in addition to routine blood tests, endoscopy, abdominal computed tomography (CT) and other clinical exams, which had not revealed any abnormal findings suggestive of the origin of the elevated CA 19-9 levels.
RESULTS: Of the 17 patients, gallbladder sludge was detected in 16 patients (94.1%) and common bile duct sludge was observed in 3 patients (17.6%). After the administration of ursodeoxycholic acid to 12 of the patients with gallbladder sludge, CA 19-9 levels normalized in 6 of the patients after a median of 4.5 mo.
CONCLUSION: EUS is a useful diagnostic method for patients with elevated CA 19-9 levels of obscure origin, even if the reason for abnormal levels of this serum marker cannot be determined through prior examinations, including abdominal CT.

Entities:  

Keywords:  Carbohydrate antigen 19-9; Endoscopic ultrasonography; Gallbladder; Ursodeoxycholic acid

Year:  2013        PMID: 23678379      PMCID: PMC3653025          DOI: 10.4253/wjge.v5.i5.251

Source DB:  PubMed          Journal:  World J Gastrointest Endosc


  26 in total

1.  Effects of ursodeoxycholic acid and aspirin on the formation of lithogenic bile and gallstones during loss of weight.

Authors:  P H Broomfield; R Chopra; R C Sheinbaum; G G Bonorris; A Silverman; L J Schoenfield; J W Marks
Journal:  N Engl J Med       Date:  1988-12-15       Impact factor: 91.245

Review 2.  Pathogenesis and treatment of gallstones.

Authors:  D E Johnston; M M Kaplan
Journal:  N Engl J Med       Date:  1993-02-11       Impact factor: 91.245

3.  High accuracy sonographic recognition of gallstones.

Authors:  P C Hessler; D S Hill; F M Deforie; A F Rocco
Journal:  AJR Am J Roentgenol       Date:  1981-03       Impact factor: 3.959

4.  Gray-scale ultrasonography as a screening procedure in the detection of gallbladder disease.

Authors:  D M McIntosh; H F Penney
Journal:  Radiology       Date:  1980-09       Impact factor: 11.105

5.  A case of common bile duct stone with cholangitis presenting an extraordinarily high serum CA19-9 value.

Authors:  T Murohisa; H Sugaya; I Tetsuka; T Suzuki; T Harada
Journal:  Intern Med       Date:  1992-04       Impact factor: 1.271

6.  [Therapeutic efficacy of ursodeoxycholic acid in persistent gallbladder lithiasis and persistent biliary sludge: preliminary results of a multicenter experience].

Authors:  C Guma; L Viola; C Apestegui; L Pinchuk; J Groppa; J Michelini; B Martínez; R Bolaños; L Toselli
Journal:  Acta Gastroenterol Latinoam       Date:  1994

7.  Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population.

Authors:  Jee-Eun Kim; Kyu Taek Lee; Jong Kyun Lee; Seung Woon Paik; Jong Chul Rhee; Kyoo Wan Choi
Journal:  J Gastroenterol Hepatol       Date:  2004-02       Impact factor: 4.029

8.  Origin and fate of biliary sludge.

Authors:  S P Lee; K Maher; J F Nicholls
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

9.  Gallbladder sludge: spontaneous course and incidence of complications in patients without stones.

Authors:  P Janowitz; W Kratzer; T Zemmler; J Tudyka; J G Wechsler
Journal:  Hepatology       Date:  1994-08       Impact factor: 17.425

10.  Combined endoscopic ultrasound and stimulated biliary drainage in cholecystitis and microlithiasis--diagnoses and outcomes.

Authors:  J E Dill; S Hill; J Callis; L Berkhouse; P Evans; D Martin; S T Palmer
Journal:  Endoscopy       Date:  1995-08       Impact factor: 10.093

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.